Evidence map›Paper›PMID 35992901›Full record

ReviewFrontiers in neuroscience2022

A retinal contribution to opioid-induced sleep disorders?

Nikolas Bergum, Casey-Tyler Berezin, Jozsef Vigh

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Nikolas BergumDepartment of Biomedical Sciences, Colorado State University, Fort Collins, CO, United States.
Casey-Tyler BerezinProgram in Cell and Molecular Biology, Colorado State University, Fort Collins, CO, United States.
Jozsef VighDepartment of Biomedical Sciences, Colorado State University, Fort Collins, CO, United States.
Colorado State University · US

Funding

Predoctoral Training in Quantitative Cell & Molecular BiologyT32GM132057 · NIGMS · COLORADO STATE UNIVERSITY · PI Karen Marie Dobos, Brian Munsky · 2019 to 2026
$2.9M
Opioid Modulation of Retinal Ganglion Cells Providing Photoentrainment of the Circadian ClockR01EY029227 · NEI · COLORADO STATE UNIVERSITY · PI Jozsef Vigh · 2019 to 2026
$2.6M
NEI NIH HHS R01 EY029227NIGMS NIH HHS T32 GM132057
6 · The paper itself

Abstract

Chronic opioid use is linked to persistent and severe sleep/wake disturbances in patients. These opioid-related sleep problems increase risk for developing opioid dependence, mood disorders and in turn overdose in chronic pain patients receiving opioid therapy. Despite the well-established link between long-term opioid use and sleep disorders, the mechanism by which opioids perturb sleep remains unclear. Interestingly, animal studies indicate that opioids disrupt sleep/wake behaviors by altering an animal's ability to synchronize their circadian rhythms to environmental light cycles (i.e., photoentrainment). A specific subset of retinal cells known as intrinsically photosensitive retinal ganglion cells (ipRGCs) that express μ-opioid receptors are exclusively responsible for transmitting environmental light information to sleep/circadian centers in the brain. Thus, this review will focus on the effect of opioids on ipRGCs and their projection regions that are involved in the photoentrainment of sleep/wake behaviors. Lastly, we discuss the viability of ipRGCs as a potential therapeutic target for treating opioid-related sleep/wake problems.

Indexed as

addictioncircadian rhythmhypothalamusmelanopsinopioidsretinasleepsuprachiasmatic nucleus

Identifiers

PMID35992901
PMCPMC9388851
OpenAlexW4289888122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.